AstraZeneca gets CDSCO panel nod to study anticancer drug Datopotamab deruxtecan
Advertisement
New Delhi: Pharmaceutical major, AstraZeneca has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct Phase III clinical trial of the anticancer drug Datopotamab deruxtecan.
This came after the drug major AstraZeneca presented Phase III clinical trial protocol no D926NC, version 1.0 dated 15-07-2022, local clinical trial protocol addendum IND-1, version 1.0 dated 11-08-2022 before the committee.
Datopotamab deruxtecan, an antibody-drug conjugate directed against trophoblast cell surface antigen-2 (Trop-2), is showing promise as a treatment for relapsed or refractory advanced triple-negative breast cancer.
Datopotamab deruxtecan is an antibody-drug conjugate with three components: a humanized anti–Trop-2 IgG1 monoclonal antibody attached to a topoisomerase 1 inhibitor payload via a tetrapeptide-based cleavable linker. It was designed with these key attributes: topoisomerase 1 inhibition as the payload mechanism of action; a payload with high potency, short systemic half-life, and stable linker; optimized drug-to-antibody ratio; tumour-selective cleavable linker; and bystander antitumor effect,
At the recent SEC meeting for oncology and hematology held on December 9th 2022, the expert panel reviewed the Phase III clinical trial protocol of the anticancer drug Datopotamab Deruxtecan (Dato-DXD).
After detailed deliberation, the committee recommended the grant of permission to conduct the study of the anticancer drug Datopotamab deruxtecan.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.